🇪🇺 Ranexa in European Union

EMA authorised Ranexa on 8 July 2008

Marketing authorisation

EMA — authorised 8 July 2008

  • Application: EMEA/H/C/000805
  • Marketing authorisation holder: Menarini International Operations Luxembourg S.A. (MIOL)
  • Local brand name: Ranexa (previously Latixa)
  • Indication: Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
  • Status: approved

Read official source →

Ranexa in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Ranexa approved in European Union?

Yes. EMA authorised it on 8 July 2008.

Who is the marketing authorisation holder for Ranexa in European Union?

Menarini International Operations Luxembourg S.A. (MIOL) holds the EU marketing authorisation.